MX2022011765A - Usos novedosos de xantenos halogenados en oncologia y virologia. - Google Patents

Usos novedosos de xantenos halogenados en oncologia y virologia.

Info

Publication number
MX2022011765A
MX2022011765A MX2022011765A MX2022011765A MX2022011765A MX 2022011765 A MX2022011765 A MX 2022011765A MX 2022011765 A MX2022011765 A MX 2022011765A MX 2022011765 A MX2022011765 A MX 2022011765A MX 2022011765 A MX2022011765 A MX 2022011765A
Authority
MX
Mexico
Prior art keywords
mammalian
response
halogenated xanthene
mammalian subject
immunogen
Prior art date
Application number
MX2022011765A
Other languages
English (en)
Inventor
Eric A Wachter
Aru Narendran
Dominic Rodrigues
Edward V Pershing
Bruce Horowitz
Original Assignee
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provectus Pharmatech Inc filed Critical Provectus Pharmatech Inc
Publication of MX2022011765A publication Critical patent/MX2022011765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar una infección viral de un sujeto mamífero que comprende administrar una cantidad inhibidora de virus de un xanteno halogenado, una sal farmacéuticamente aceptable, un éster de alquilo o amida o éster aromático o derivado de amida del mismo como se describe en la presente, al sujeto mamífero. Un método para inducir una respuesta de interferón tipo I en un sujeto mamífero que presenta una infección microbiana, tumor canceroso o malignidad hematológica que comprende administrar una cantidad de un xanteno halogenado como se mencionó anteriormente, eficaz para inducir la respuesta de interferón tipo I. Un método para mejorar una respuesta inmune específica de un inmunógeno de mamífero que comprende poner en contacto células de mamífero, in vivo o presentes en un medio de soporte de crecimiento de células de mamífero, con una cantidad eficaz de un xanteno halogenado como adyuvante como se mencionó anteriormente, y un inmunógeno al que esa respuesta se va a mejorar.
MX2022011765A 2020-03-26 2021-03-25 Usos novedosos de xantenos halogenados en oncologia y virologia. MX2022011765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000231P 2020-03-26 2020-03-26
PCT/US2021/024185 WO2021195400A1 (en) 2020-03-26 2021-03-25 Novel uses of halogenated xanthenes in oncology and virology

Publications (1)

Publication Number Publication Date
MX2022011765A true MX2022011765A (es) 2022-11-09

Family

ID=77855092

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022011765A MX2022011765A (es) 2020-03-26 2021-03-25 Usos novedosos de xantenos halogenados en oncologia y virologia.
MX2022011867A MX2022011867A (es) 2020-03-26 2021-09-29 Xantenos halogenados como adyuvantes en vacunas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011867A MX2022011867A (es) 2020-03-26 2021-09-29 Xantenos halogenados como adyuvantes en vacunas.

Country Status (9)

Country Link
US (2) US11975106B2 (es)
EP (3) EP4103283A4 (es)
JP (3) JP2023519382A (es)
KR (3) KR20230005181A (es)
CN (3) CN115916343A (es)
AU (3) AU2021242300A1 (es)
CA (3) CA3172124A1 (es)
MX (2) MX2022011765A (es)
WO (3) WO2021195400A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
MX2022011765A (es) * 2020-03-26 2022-11-09 Provectus Pharmatech Inc Usos novedosos de xantenos halogenados en oncologia y virologia.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA993795A (en) 1970-12-10 1976-07-27 Richardson-Merrell (Canada) Ltd. Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith
US3859286A (en) * 1970-12-11 1975-01-07 Richardson Merrell Inc Bis-basic ketones of xanthene and xanthen-9-one
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
DE471794T1 (de) * 1989-05-11 1992-07-23 Oklahoma Medical Research Foundation, Oklahoma, Okla., Us Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen.
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
US7390668B2 (en) 1996-10-30 2008-06-24 Provectus Pharmatech, Inc. Intracorporeal medicaments for photodynamic treatment of disease
US5829448A (en) 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US20090117199A1 (en) * 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
US6254891B1 (en) * 1998-09-03 2001-07-03 Ascent Pediatrics, Inc. Extended release acetaminophen
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
WO2002062333A1 (en) * 2001-02-05 2002-08-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
PT2529626T (pt) * 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Composições e métodos para tratamento ou prevenção do cancro do cólon
KR101494055B1 (ko) 2009-09-18 2015-02-16 프로벡투스 파마슈티컬스 인코포레이티드 4,5,6,7-테트라클로로-3'',6''-다이하이드록시-2'',4'',5'',7''- 테트라요오도-3ｈ-스피로［이소벤조푸란-1,9''-잔텐］-3-온(로즈 벤갈) 및 관련 잔텐의 합성 방법
US9273022B2 (en) 2009-09-18 2016-03-01 Provectus Pharmaceuticals, Inc. Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes
WO2011133728A2 (en) * 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US8785434B2 (en) * 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US9107887B2 (en) * 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
CA2927009C (en) * 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
US10130658B2 (en) * 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
ES2964399T3 (es) * 2018-05-16 2024-04-05 Provectus Pharmatech Inc Actividad antitumoral in vitro y xenoinjerto de un xanteno halogenado contra tumores sólidos pediátricos refractarios
WO2020028532A1 (en) 2018-08-02 2020-02-06 The Board Of Regents Of The University Of Texas System Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease
MX2022011765A (es) * 2020-03-26 2022-11-09 Provectus Pharmatech Inc Usos novedosos de xantenos halogenados en oncologia y virologia.

Also Published As

Publication number Publication date
EP4103283A4 (en) 2024-02-28
KR20230005185A (ko) 2023-01-09
EP4106814A4 (en) 2024-05-01
CN115666646A (zh) 2023-01-31
US20210299055A1 (en) 2021-09-30
JP2023519382A (ja) 2023-05-10
WO2021195400A1 (en) 2021-09-30
WO2021195573A1 (en) 2021-09-30
US11975106B2 (en) 2024-05-07
EP4106814A1 (en) 2022-12-28
KR20230005181A (ko) 2023-01-09
WO2022203718A1 (en) 2022-09-29
CA3172420A1 (en) 2023-03-29
KR20230165107A (ko) 2023-12-05
AU2021242300A1 (en) 2022-10-13
JP7475481B2 (ja) 2024-04-26
AU2021433087A1 (en) 2022-10-20
CA3172124A1 (en) 2021-09-30
JP2023526159A (ja) 2023-06-21
AU2021242347A1 (en) 2022-10-20
CN115916190A (zh) 2023-04-04
JP2023519383A (ja) 2023-05-10
CA3172134A1 (en) 2021-09-30
EP4103283A1 (en) 2022-12-21
MX2022011867A (es) 2022-11-09
US20210299083A1 (en) 2021-09-30
CN115916343A (zh) 2023-04-04
EP4106749A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
MX2022011765A (es) Usos novedosos de xantenos halogenados en oncologia y virologia.
Münz et al. Immune escape by Epstein–Barr virus associated malignancies
MX2021012285A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
MX2021015675A (es) Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
Hirschberg et al. Photodynamic therapy mediated immune therapy of brain tumors
Courdi et al. The depth-dependent radiation response of human melanoma cells exposed to 65 MeV protons
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
TW201835327A (zh) 一種重組單純皰疹病毒及其用途
RU2011149458A (ru) Онкологические аденовирусы для лечения рака
JP2010516259A5 (es)
WO2003061591A3 (en) Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
CN105497886A (zh) 乙肝核心抗原病毒样颗粒作为肿瘤治疗性疫苗载体的应用
NZ606549A (en) Inactivated varicella zoster virus vaccines, methods of production, and uses thereof
EP0400477B1 (en) Polymeric anhydride of magnesium and proteic ammonium phospholinoleate with antiviral, antineoplastic and immunostimulant properties
AU2017203173A1 (en) Method For The Production Of Protein Complexes And Vaccine Compositions Comprising The Same
CN102153658A (zh) 肿瘤抗原、dc肿瘤疫苗及其制备方法
Zhang et al. Inhibitory and immunological effects induced by the combination of photodynamic therapy and dendritic cells on mouse transplanted hepatoma
MX2023001187A (es) Composiciones y métodos para una vacunación mejorada.
CN108575750A (zh) 绞股蓝组培快繁培养基及应用其的绞股蓝组培快繁工艺
RU2572569C1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОДКОЖНЫХ КСЕНОГРАФТОВ КЛЕТОЧНОЙ ЛИНИИ МЕЛАНОМЫ КОЖИ ЧЕЛОВЕКА mel Cher С МУТАЦИЕЙ V600E BRAF ДЛЯ ДОКЛИНИЧЕСКОГО ИЗУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ТАРГЕТНЫХ СРЕДСТВ
Batmonkh et al. In vivo anticancer activity of lysates from Trypanosoma cruzi of different genetic groups
CY1108781T1 (el) Εμβολιο ψαριων
CN107007830A (zh) 一种无毒株弓形体和中药多糖佐剂组合物的用途、疫苗及制备方法
CN111635885A (zh) 一种提高脐带间质干细胞抗氧化能力的培养方法
CN104117060A (zh) 一种肿瘤疫苗及其制备方法